XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can't continue continuous infusion therapy
Phase 2
- Conditions
- advanced and recurrent colorectal cancer
- Registration Number
- JPRN-UMIN000003961
- Lead Sponsor
- Kochi Health Sciences Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe renal failure 2)severe hypersensitivity to have a history fluorouracil,lebohorinatokarushiumu, platinum, bevacizumab 3)activity with multiple cancers(After which no more than five years of activity) 4)brain metastases(only when using bevacizumab) 5)FOLFOX(+bevacizumab)treatment for 3 or more months after 6)In addition, if deemed unsuitable to participate in this study is the responsible physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does XELOX plus bevacizumab compare to FOLFOX plus bevacizumab in advanced colorectal cancer patients with infusion therapy intolerance?
What molecular mechanisms underlie bevacizumab's anti-VEGF activity in combination with oxaliplatin-based regimens for recurrent colorectal cancer?
Which biomarkers correlate with improved progression-free survival in JPRN-UMIN000003961's intermittent bevacizumab regimen?
What are the safety profiles of capecitabine/oxaliplatin vs. 5-FU/oxaliplatin combinations with bevacizumab in phase II colorectal cancer trials?
How does the XELOX-bevacizumab regimen impact quality of life metrics compared to standard FOLFOX-bevacizumab in metastatic colorectal cancer patients?